NEW YORK, April 19 –Genomic Solutions and PerkinElmer have settled a lawsuit over PerkinElmer’s stake in Genomic Solutions stock, the companies said Thursday. 

Genomic Solutions also released financial results for the first quarter of 2001 Thursday, reporting that revenues increased 10 percent over the year-ago quarter to $4.4 million, and that losses totaled 12 cents per share, 4 cents more than Wall Street had expected, according to a survey of one broker conducted by FirstCall/Thomson Financial.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.